Browse ITGA1

Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane; Single-pass type I membrane protein.
Domain PF01839 FG-GAP repeat
PF08441 Integrin alpha
PF00092 von Willebrand factor type A domain
Function

Integrin alpha-1/beta-1 is a receptor for laminin and collagen. It recognizes the proline-hydroxylated sequence G-F-P-G-E-R in collagen. Involved in anchorage-dependent, negative regulation of EGF-stimulated cell growth.

> Gene Ontology
 
Biological Process GO:0000187 activation of MAPK activity
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006470 protein dephosphorylation
GO:0006936 muscle contraction
GO:0007160 cell-matrix adhesion
GO:0007173 epidermal growth factor receptor signaling pathway
GO:0007229 integrin-mediated signaling pathway
GO:0008015 blood circulation
GO:0010921 regulation of phosphatase activity
GO:0010922 positive regulation of phosphatase activity
GO:0016311 dephosphorylation
GO:0030198 extracellular matrix organization
GO:0030593 neutrophil chemotaxis
GO:0030595 leukocyte chemotaxis
GO:0031589 cell-substrate adhesion
GO:0032147 activation of protein kinase activity
GO:0032516 positive regulation of phosphoprotein phosphatase activity
GO:0033674 positive regulation of kinase activity
GO:0035150 regulation of tube size
GO:0035303 regulation of dephosphorylation
GO:0035304 regulation of protein dephosphorylation
GO:0035306 positive regulation of dephosphorylation
GO:0035307 positive regulation of protein dephosphorylation
GO:0038127 ERBB signaling pathway
GO:0042058 regulation of epidermal growth factor receptor signaling pathway
GO:0042059 negative regulation of epidermal growth factor receptor signaling pathway
GO:0042311 vasodilation
GO:0043062 extracellular structure organization
GO:0043405 regulation of MAP kinase activity
GO:0043406 positive regulation of MAP kinase activity
GO:0043410 positive regulation of MAPK cascade
GO:0043523 regulation of neuron apoptotic process
GO:0043525 positive regulation of neuron apoptotic process
GO:0043666 regulation of phosphoprotein phosphatase activity
GO:0045123 cellular extravasation
GO:0045860 positive regulation of protein kinase activity
GO:0050880 regulation of blood vessel size
GO:0050900 leukocyte migration
GO:0051402 neuron apoptotic process
GO:0060326 cell chemotaxis
GO:0070997 neuron death
GO:0071621 granulocyte chemotaxis
GO:0071900 regulation of protein serine/threonine kinase activity
GO:0071902 positive regulation of protein serine/threonine kinase activity
GO:0090066 regulation of anatomical structure size
GO:0097529 myeloid leukocyte migration
GO:0097530 granulocyte migration
GO:1901184 regulation of ERBB signaling pathway
GO:1901185 negative regulation of ERBB signaling pathway
GO:1901214 regulation of neuron death
GO:1901216 positive regulation of neuron death
GO:1990266 neutrophil migration
Molecular Function GO:0005518 collagen binding
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
GO:0098631 protein binding involved in cell adhesion
GO:0098634 protein binding involved in cell-matrix adhesion
GO:0098639 collagen binding involved in cell-matrix adhesion
Cellular Component GO:0001669 acrosomal vesicle
GO:0005924 cell-substrate adherens junction
GO:0005925 focal adhesion
GO:0008305 integrin complex
GO:0009897 external side of plasma membrane
GO:0030055 cell-substrate junction
GO:0030141 secretory granule
GO:0034665 integrin alpha1-beta1 complex
GO:0043025 neuronal cell body
GO:0043204 perikaryon
GO:0043235 receptor complex
GO:0044297 cell body
GO:0045121 membrane raft
GO:0045178 basal part of cell
GO:0097223 sperm part
GO:0098552 side of membrane
GO:0098589 membrane region
GO:0098636 protein complex involved in cell adhesion
GO:0098802 plasma membrane receptor complex
GO:0098857 membrane microdomain
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG hsa04151 PI3K-Akt signaling pathway
hsa04510 Focal adhesion
hsa04512 ECM-receptor interaction
hsa04640 Hematopoietic cell lineage
hsa04810 Regulation of actin cytoskeleton
Reactome R-HSA-422475: Axon guidance
R-HSA-447041: CHL1 interactions
R-HSA-1266738: Developmental Biology
R-HSA-1474244: Extracellular matrix organization
R-HSA-109582: Hemostasis
R-HSA-216083: Integrin cell surface interactions
R-HSA-373760: L1CAM interactions
R-HSA-3000157: Laminin interactions
R-HSA-397014: Muscle contraction
R-HSA-416700: Other semaphorin interactions
R-HSA-75892: Platelet Adhesion to exposed collagen
R-HSA-373755: Semaphorin interactions
R-HSA-445355: Smooth Muscle Contraction
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ITGA1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ITGA1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
28018343MelanomaPromote immunityVLA-1-expressing TIL frequently co-express CD69 and CD103, indicating tissue-resident memory T cells (TRM) differentiation. In addition,in vivo blockade of either VLA-1 or CD103 significantly impaired control of subcutaneous tumors.
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ITGA1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ITGA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.6410.192
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.2240.416
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.210.847
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3410.448
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7750.732
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2060.942
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2830.614
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0520.975
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.620.724
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.6390.653
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5970.429
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.3110.00999
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ITGA1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277305.5-5.50.572
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275906.8-6.80.304
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.517.6-8.10.64
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.516.7-4.21
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.83.712.10.224
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.87.111.70.602
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ITGA1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ITGA1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ITGA1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ITGA1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ITGA1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ITGA1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolITGA1
Nameintegrin, alpha 1
Aliases VLA1; CD49a; CD49 antigen-like family member A; VLA-1; laminin and collagen receptor; very late activation p ......
Chromosomal Location5q11.1
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ITGA1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.